Progress and clinical application of TRAIL-induced apoptosis in cancer

Chinese Pharmacological Bulletin

Volumn 19, Issue 9, 2003, Pages 976-981

  Fan, Qing Lin ^a,b   Song, Li Hua ^b   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Biology Institute   (China)

Author keywords

Caspase; Cell apoptosis; Death receptor; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CELL RECEPTOR; CYTOCHROME C; PROTEIN DR4; PROTEIN DR5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CHIMPANZEE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME RELEASE; GENE FUNCTION; MONKEY; MULTIGENE FAMILY; NONHUMAN; PROTEIN DEGRADATION; TUMOR CELL;

EID: 0242386353     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995;3(6):673-82
2. Pitti RM, Marsters SA, Ruppert S et al. induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Boil Chem 1996;271(22):12687-90
3. Pan G, Rorke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science, 1997;276(5309):111-3
4. Screaton GR, Mongkolsapaya AM, Xu XN et al. TRICK2 a new alternatively spliced receptor that transduces the cytotoxic signaling from TRAIL. Curr Biol, 1997;7(9):693-6
5. Degli-Esposti MA, Smolak PJ, Walczak H et al. Cloning and characterization of TRAIL-R3 a novel member of the emerging TRAIL receptor family. J Exp Med, 1997;186(7):1165-70
6. Marsters SA, Scheridan JP, Pitti RM et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Bio, 1997;7(12):1003-6
7. Enery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Boil Chem, 1998; 273(23):14363-7
8. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligang (TRAIL) and its receptors in tumor surveillance. Apoptosis, 2002;7(5):449-59
9. Oya M, Ohtsubo M, Takayana M et al. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene, 2001;20(29):3888-96
10. Xufeng C, Karthikeyan K, Rakesh K et al. Differential roles of RelA(p56) and c-Rel subunits of nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res, 2003;63(5):1059-66
11. Gura T. How TRAIL kills cancer cell, but normal cells. Science, 1997;277(53271):768
12. Kim K, Fisher MA, Xu SQ et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res, 2000;6(2):335-46
13. Bodmer JL, Holler N, Reynard S et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol, 2000;2(4):241-3
14. Suliman A, Lan A, Datta R et al. Intracellular mechanisms of TRAIL: Apoptosis tbrough mitochondrial-dependent and independent pathways. Oncogene, 2001;20(17):2122-33
15. Yeh WC, Pompa JL, McCurrach ME et al. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science, 1998;279(5358):1954-8
16. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology, 2001;34(1):3-6
17. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligang. J Clin Invest, 1999; 104(2):155-62
18. Lawrence D, Shahaokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL version, Nat Med, 2001;7(4):383-5
19. Walczak H, Miller RE, Ariail et al, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 1999;5(2):157-63
20. Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med, 2000;6(5):564-7
21. Qin J, Chaturvedi V, Bonish B et al. Avoiding premature apoptosis of normal epidermal cells. Nat Med, 2001;7(4):385-86
22. Nitsch R, Bechmann I, Deisz RA et al. Human brain-cell death induced by TRAIL. Lancet, 2000;356(9232):827-8
23. Nicholsom DW. From bench to clinic with apoptosis-based therapeutic agents. Nature, 2000;407(6805):810-6
24. Sean KE, Louise Ah, David X et al. Preclinical studies to predict the disposition of TRAIL in humans: Characterization of in vivo efficacy, pharmacokinetics and safety. J Pharm and Exp Therap, 2001;299(1):31-8
25. Truneh A, Sharma S, Silverman C et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem, 2000;275(30):23319-25
26. Wajant H, Haas E, Schwenzer R et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein(FADD). J Biol Chem, 2000;275(32):24357-66
27. French NA, Tschopp F. The TRAIL to selective tumor death. Nat Med, 1999;5(2):146-7
28. Sun Sy, Yue P, Hong Wk et al. Augmentation of tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6. Cancer Res, 2000;60 (24):7149-55
29. Chinnaiyan Am, Prasad U, Shankar S et al. Combined effect of TRAIL and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA, 2000;97(4):1754-9